Tofacitinib
FDA Approved
Description
Tofacitinib is a Janus kinase (JAK) inhibitor used to treat autoimmune conditions. It works by blocking the activity of JAK enzymes, which are involved in inflammation and immune response.
Indications & Therapeutic Use
Idiopathic giant-cell myocarditis
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Tofacitinib
| Generic Name | Tofacitinib |
| Brands | 1 brand available |
| Active Ingredient | Tofacitinib |
| Drug Class | Idiopathic giant-cell myocarditis |
| Manufacturer | Pfizer |
| Dosage Forms | Oral tablet |
| Medical Code | L04AA29 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02147714 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes